MTOR and cancer: In the clinic, a phase I trial (NCT00949949) was performed to determine the maximum tolerated dose (MTD) of mTOR inhibitor everolimus (5 mg) combined with either gemcitabine (800 mg/m2, Cohort I) or gemcitabine plus cisplatin (12.5 mg/m2, Cohort II) in cancers.